1
|
Terrett JA, Ly JQ, Katavolos P, Hasselgren C, Laing S, Zhong F, Villemure E, Déry M, Larouche-Gauthier R, Chen H, Shore DG, Lee WP, Suto E, Johnson K, Brooks M, Stablein A, Beaumier F, Constantineau-Forget L, Grand-Maître C, Lépissier L, Ciblat S, Sturino C, Chen Y, Hu B, Elstrott J, Gandham V, Joseph V, Booler H, Cain G, Chou C, Fullerton A, Lepherd M, Stainton S, Torres E, Urban K, Yu L, Zhong Y, Bao L, Chou KJ, Lin J, Zhang W, La H, Liu L, Mulder T, Chen J, Chernov-Rogan T, Johnson AR, Hackos DH, Leahey R, Shields SD, Balestrini A, Riol-Blanco L, Safina BS, Volgraf M, Magnuson S, Kakiuchi-Kiyota S. Discovery of TRPA1 Antagonist GDC-6599: Derisking Preclinical Toxicity and Aldehyde Oxidase Metabolism with a Potential First-in-Class Therapy for Respiratory Disease. J Med Chem 2024; 67:3287-3306. [PMID: 38431835 DOI: 10.1021/acs.jmedchem.3c02121] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 03/05/2024]
Abstract
Transient receptor potential ankyrin 1 (TRPA1) is a nonselective calcium ion channel highly expressed in the primary sensory neurons, functioning as a polymodal sensor for exogenous and endogenous stimuli, and has been implicated in neuropathic pain and respiratory disease. Herein, we describe the optimization of potent, selective, and orally bioavailable TRPA1 small molecule antagonists with strong in vivo target engagement in rodent models. Several lead molecules in preclinical single- and short-term repeat-dose toxicity studies exhibited profound prolongation of coagulation parameters. Based on a thorough investigative toxicology and clinical pathology analysis, anticoagulation effects in vivo are hypothesized to be manifested by a metabolite─generated by aldehyde oxidase (AO)─possessing a similar pharmacophore to known anticoagulants (i.e., coumarins, indandiones). Further optimization to block AO-mediated metabolism yielded compounds that ameliorated coagulation effects in vivo, resulting in the discovery and advancement of clinical candidate GDC-6599, currently in Phase II clinical trials for respiratory indications.
Collapse
Affiliation(s)
| | | | | | | | | | | | | | - Martin Déry
- Paraza Pharma, Incorporated, 2525 Avenue Marie-Curie, Montreal, Quebec H4S 2E1, Canada
| | | | | | | | | | | | | | - Marjory Brooks
- Department of Population Medicine and Diagnostic Sciences, Cornell University College of Veterinary Medicine, Ithaca, New York 14853, United States
| | - Alyssa Stablein
- Department of Population Medicine and Diagnostic Sciences, Cornell University College of Veterinary Medicine, Ithaca, New York 14853, United States
| | - Francis Beaumier
- Paraza Pharma, Incorporated, 2525 Avenue Marie-Curie, Montreal, Quebec H4S 2E1, Canada
| | | | - Chantal Grand-Maître
- Paraza Pharma, Incorporated, 2525 Avenue Marie-Curie, Montreal, Quebec H4S 2E1, Canada
| | - Luce Lépissier
- Paraza Pharma, Incorporated, 2525 Avenue Marie-Curie, Montreal, Quebec H4S 2E1, Canada
| | - Stéphane Ciblat
- Paraza Pharma, Incorporated, 2525 Avenue Marie-Curie, Montreal, Quebec H4S 2E1, Canada
| | - Claudio Sturino
- Paraza Pharma, Incorporated, 2525 Avenue Marie-Curie, Montreal, Quebec H4S 2E1, Canada
| | - Yong Chen
- Pharmaron-Beijing Company Limited, 6 Taihe Road BDA, Beijing 100176, PR China
| | - Baihua Hu
- Pharmaron-Beijing Company Limited, 6 Taihe Road BDA, Beijing 100176, PR China
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
2
|
Lu Z, Ju M, Wang Y, Meinhardt JM, Martinez Alvarado JI, Villemure E, Terrett JA, Lin S. Regioselective aliphatic C-H functionalization using frustrated radical pairs. Nature 2023; 619:514-520. [PMID: 37407819 PMCID: PMC10530363 DOI: 10.1038/s41586-023-06131-3] [Citation(s) in RCA: 10] [Impact Index Per Article: 10.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/11/2023] [Accepted: 04/25/2023] [Indexed: 07/07/2023]
Abstract
Frustrated Lewis pairs (FLPs) are well documented for the activation of small molecules such as dihydrogen and carbon dioxide1-4. Although canonical FLP chemistry is heterolytic in nature, recent work has shown that certain FLPs can undergo single-electron transfer to afford radical pairs5. Owing to steric encumbrance and/or weak bonding association, these radicals do not annihilate one another, and they have thus been named frustrated radical pairs (FRPs). Notable preliminary results suggest that FRPs may be useful reagents in chemical synthesis6-8, although their applications remain limited. Here we demonstrate that the functionalization of C(sp3)-H bonds can be accomplished using a class of FRPs generated from disilazide donors and an N-oxoammonium acceptor. Together, these species undergo single-electron transfer to generate a transient and persistent radical pair capable of cleaving unactivated C-H bonds to furnish aminoxylated products. By tuning the structure of the donor, it is possible to control regioselectivity and tailor reactivity towards tertiary, secondary or primary C-H bonds. Mechanistic studies lend strong support for the formation and involvement of radical pairs in the target reaction.
Collapse
Affiliation(s)
- Zhipeng Lu
- Department of Chemistry and Chemical Biology, Cornell University, Ithaca, NY, USA
| | - Minsoo Ju
- Department of Chemistry and Chemical Biology, Cornell University, Ithaca, NY, USA
| | - Yi Wang
- Department of Chemistry and Chemical Biology, Cornell University, Ithaca, NY, USA
| | - Jonathan M Meinhardt
- Department of Chemistry and Chemical Biology, Cornell University, Ithaca, NY, USA
| | | | - Elisia Villemure
- Department of Discovery Chemistry, Genentech, Inc., South San Francisco, CA, USA
| | - Jack A Terrett
- Department of Discovery Chemistry, Genentech, Inc., South San Francisco, CA, USA
| | - Song Lin
- Department of Chemistry and Chemical Biology, Cornell University, Ithaca, NY, USA.
| |
Collapse
|
3
|
Novaes LFT, Ho JSK, Mao K, Liu K, Tanwar M, Neurock M, Villemure E, Terrett JA, Lin S. Exploring Electrochemical C(sp 3)-H Oxidation for the Late-Stage Methylation of Complex Molecules. J Am Chem Soc 2022; 144:1187-1197. [PMID: 35015533 DOI: 10.1021/jacs.1c09412] [Citation(s) in RCA: 43] [Impact Index Per Article: 21.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023]
Abstract
The "magic methyl" effect, a dramatic boost in the potency of biologically active compounds from the incorporation of a single methyl group, provides a simple yet powerful strategy employed by medicinal chemists in the drug discovery process. Despite significant advances, methodologies that enable the selective C(sp3)-H methylation of structurally complex medicinal agents remain very limited. In this work, we disclose a modular, efficient, and selective strategy for the α-methylation of protected amines (i.e., amides, carbamates, and sulfonamides) by means of electrochemical oxidation. Mechanistic analysis guided our development of an improved electrochemical protocol on the basis of the classic Shono oxidation reaction, which features broad reaction scope, high functional group compatibility, and operational simplicity. Importantly, this reaction system is amenable to the late-stage functionalization of complex targets containing basic nitrogen groups that are prevalent in medicinally active agents. When combined with organozinc-mediated C-C bond formation, our protocol enabled the direct methylation of a myriad of amine derivatives including those that have previously been explored for the "magic methyl" effect. This synthesis strategy thus circumvents multistep de novo synthesis that is currently necessary to access such compounds and has the potential to accelerate drug discovery efforts.
Collapse
Affiliation(s)
- Luiz F T Novaes
- Department of Chemistry and Chemical Biology, Cornell University, Ithaca, New York 14850, United States
| | - Justin S K Ho
- Department of Chemistry and Chemical Biology, Cornell University, Ithaca, New York 14850, United States
| | - Kaining Mao
- Department of Chemistry and Chemical Biology, Cornell University, Ithaca, New York 14850, United States
| | - Kaida Liu
- Department of Chemical Engineering and Materials Science, University of Minnesota, Minneapolis, Minnesota 55455, United States
| | - Mayank Tanwar
- Department of Chemical Engineering and Materials Science, University of Minnesota, Minneapolis, Minnesota 55455, United States
| | - Matthew Neurock
- Department of Chemical Engineering and Materials Science, University of Minnesota, Minneapolis, Minnesota 55455, United States
| | - Elisia Villemure
- Department of Discovery Chemistry, Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States
| | - Jack A Terrett
- Department of Discovery Chemistry, Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States
| | - Song Lin
- Department of Chemistry and Chemical Biology, Cornell University, Ithaca, New York 14850, United States
| |
Collapse
|
4
|
Villemure E, Terrett JA, Larouche-Gauthier R, Déry M, Chen H, Reese RM, Shields SD, Chen J, Magnuson S, Volgraf M. A Retrospective Look at the Impact of Binding Site Environment on the Optimization of TRPA1 Antagonists. ACS Med Chem Lett 2021; 12:1230-1237. [PMID: 34413952 DOI: 10.1021/acsmedchemlett.1c00305] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/27/2021] [Accepted: 07/02/2021] [Indexed: 12/27/2022] Open
Abstract
Transient receptor potential ankyrin 1 (TRPA1) antagonists have generated broad interest in the pharmaceutical industry for the treatment of both pain and asthma. Over the past decade, multiple antagonist classes have been reported in the literature with a wide range of structural diversity. Our own work has focused on the development of proline sulfonamide and hypoxanthine-based antagonists, two antagonist classes with distinct physicochemical properties and pharmacokinetic (PK) trends. Late in our discovery program, cryogenic electron microscopy (cryoEM) studies revealed two different antagonist binding sites: a membrane-exposed proline sulfonamide transmembrane site and an intracellular hypoxanthine site near the membrane interface. A retrospective look at the discovery program reveals how the different binding sites, and their location relative to the cell membrane, influenced the optimization trajectories and overall drug profiles of each antagonist class.
Collapse
Affiliation(s)
- Elisia Villemure
- Department of Discovery Chemistry, Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States
| | - Jack A. Terrett
- Department of Discovery Chemistry, Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States
| | | | - Martin Déry
- Paraza Pharma, Inc. 2525 Avenue Marie-Curie, Montréal, Québec H4S 2E1, Canada
| | - Huifen Chen
- Department of Discovery Chemistry, Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States
| | - Rebecca M. Reese
- Department of Neuroscience, Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States
| | - Shannon D. Shields
- Department of Neuroscience, Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States
| | - Jun Chen
- Department of Biochemical and Cellular Pharmacology, Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States
| | - Steven Magnuson
- Department of Discovery Chemistry, Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States
| | - Matthew Volgraf
- Department of Discovery Chemistry, Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States
| |
Collapse
|
5
|
Terrett JA, Chen H, Shore DG, Villemure E, Larouche-Gauthier R, Déry M, Beaumier F, Constantineau-Forget L, Grand-Maître C, Lépissier L, Ciblat S, Sturino C, Chen Y, Hu B, Lu A, Wang Y, Cridland AP, Ward SI, Hackos DH, Reese RM, Shields SD, Chen J, Balestrini A, Riol-Blanco L, Lee WP, Liu J, Suto E, Wu X, Zhang J, Ly JQ, La H, Johnson K, Baumgardner M, Chou KJ, Rohou A, Rougé L, Safina BS, Magnuson S, Volgraf M. Tetrahydrofuran-Based Transient Receptor Potential Ankyrin 1 (TRPA1) Antagonists: Ligand-Based Discovery, Activity in a Rodent Asthma Model, and Mechanism-of-Action via Cryogenic Electron Microscopy. J Med Chem 2021; 64:3843-3869. [PMID: 33749283 DOI: 10.1021/acs.jmedchem.0c02023] [Citation(s) in RCA: 18] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/23/2022]
Abstract
Transient receptor potential ankyrin 1 (TRPA1) is a nonselective calcium-permeable ion channel highly expressed in the primary sensory neurons functioning as a polymodal sensor for exogenous and endogenous stimuli and has generated widespread interest as a target for inhibition due to its implication in neuropathic pain and respiratory disease. Herein, we describe the optimization of a series of potent, selective, and orally bioavailable TRPA1 small molecule antagonists, leading to the discovery of a novel tetrahydrofuran-based linker. Given the balance of physicochemical properties and strong in vivo target engagement in a rat AITC-induced pain assay, compound 20 was progressed into a guinea pig ovalbumin asthma model where it exhibited significant dose-dependent reduction of inflammatory response. Furthermore, the structure of the TRPA1 channel bound to compound 21 was determined via cryogenic electron microscopy to a resolution of 3 Å, revealing the binding site and mechanism of action for this class of antagonists.
Collapse
Affiliation(s)
- Jack A Terrett
- Department of Discovery Chemistry, Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States
| | - Huifen Chen
- Department of Discovery Chemistry, Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States
| | - Daniel G Shore
- Department of Discovery Chemistry, Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States
| | - Elisia Villemure
- Department of Discovery Chemistry, Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States
| | | | - Martin Déry
- Paraza Pharma, Inc. 2525 Avenue Marie-Curie, Montreal, Quebec H4S 2E1, Canada
| | - Francis Beaumier
- Paraza Pharma, Inc. 2525 Avenue Marie-Curie, Montreal, Quebec H4S 2E1, Canada
| | | | | | - Luce Lépissier
- Paraza Pharma, Inc. 2525 Avenue Marie-Curie, Montreal, Quebec H4S 2E1, Canada
| | - Stéphane Ciblat
- Paraza Pharma, Inc. 2525 Avenue Marie-Curie, Montreal, Quebec H4S 2E1, Canada
| | - Claudio Sturino
- Paraza Pharma, Inc. 2525 Avenue Marie-Curie, Montreal, Quebec H4S 2E1, Canada
| | - Yong Chen
- Pharmaron-Beijing Co. Ltd., 6 Taihe Road, BDA, Beijing 100176, PR China
| | - Baihua Hu
- Pharmaron-Beijing Co. Ltd., 6 Taihe Road, BDA, Beijing 100176, PR China
| | - Aijun Lu
- Pharmaron-Beijing Co. Ltd., 6 Taihe Road, BDA, Beijing 100176, PR China
| | - Yunli Wang
- Pharmaron-Beijing Co. Ltd., 6 Taihe Road, BDA, Beijing 100176, PR China
| | - Andrew P Cridland
- Charles River Laboratories, 8/9 Spire Green Centre, Flex Meadow, Harlow, Essex CM19 5TR, United Kingdom
| | - Stuart I Ward
- Charles River Laboratories, 8/9 Spire Green Centre, Flex Meadow, Harlow, Essex CM19 5TR, United Kingdom
| | - David H Hackos
- Department of Neurosciences, Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States
| | - Rebecca M Reese
- Department of Neurosciences, Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States
| | - Shannon D Shields
- Department of Neurosciences, Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States
| | - Jun Chen
- Department of Biochemical and Cellular Pharmacology, Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States
| | - Alessia Balestrini
- Department of Discovery Immunology, Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States
| | - Lorena Riol-Blanco
- Department of Discovery Immunology, Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States
| | - Wyne P Lee
- Department of Translational Immunology, Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States
| | - John Liu
- Department of Translational Immunology, Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States
| | - Eric Suto
- Department of Translational Immunology, Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States
| | - Xiumin Wu
- Department of Translational Immunology, Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States
| | - Juan Zhang
- Department of Translational Immunology, Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States
| | - Justin Q Ly
- Department of Drug Metabolism and Pharmacokinetics, Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States
| | - Hank La
- Department of Drug Metabolism and Pharmacokinetics, Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States
| | - Kevin Johnson
- Department of Drug Metabolism and Pharmacokinetics, Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States
| | - Matt Baumgardner
- Department of Drug Metabolism and Pharmacokinetics, Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States
| | - Kang-Jye Chou
- Department of Small Molecule Pharmaceutical Sciences, Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States
| | - Alexis Rohou
- Department of Structural Biology, Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States
| | - Lionel Rougé
- Department of Structural Biology, Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States
| | - Brian S Safina
- Department of Discovery Chemistry, Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States
| | - Steven Magnuson
- Department of Discovery Chemistry, Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States
| | - Matthew Volgraf
- Department of Discovery Chemistry, Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States
| |
Collapse
|
6
|
Balestrini A, Joseph V, Dourado M, Reese RM, Shields SD, Rougé L, Bravo DD, Chernov-Rogan T, Austin CD, Chen H, Wang L, Villemure E, Shore DGM, Verma VA, Hu B, Chen Y, Leong L, Bjornson C, Hötzel K, Gogineni A, Lee WP, Suto E, Wu X, Liu J, Zhang J, Gandham V, Wang J, Payandeh J, Ciferri C, Estevez A, Arthur CP, Kortmann J, Wong RL, Heredia JE, Doerr J, Jung M, Vander Heiden JA, Roose-Girma M, Tam L, Barck KH, Carano RAD, Ding HT, Brillantes B, Tam C, Yang X, Gao SS, Ly JQ, Liu L, Chen L, Liederer BM, Lin JH, Magnuson S, Chen J, Hackos DH, Elstrott J, Rohou A, Safina BS, Volgraf M, Bauer RN, Riol-Blanco L. A TRPA1 inhibitor suppresses neurogenic inflammation and airway contraction for asthma treatment. J Exp Med 2021; 218:211821. [PMID: 33620419 PMCID: PMC7918756 DOI: 10.1084/jem.20201637] [Citation(s) in RCA: 51] [Impact Index Per Article: 17.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/31/2020] [Revised: 10/19/2020] [Accepted: 12/23/2020] [Indexed: 12/31/2022] Open
Abstract
Despite the development of effective therapies, a substantial proportion of asthmatics continue to have uncontrolled symptoms, airflow limitation, and exacerbations. Transient receptor potential cation channel member A1 (TRPA1) agonists are elevated in human asthmatic airways, and in rodents, TRPA1 is involved in the induction of airway inflammation and hyperreactivity. Here, the discovery and early clinical development of GDC-0334, a highly potent, selective, and orally bioavailable TRPA1 antagonist, is described. GDC-0334 inhibited TRPA1 function on airway smooth muscle and sensory neurons, decreasing edema, dermal blood flow (DBF), cough, and allergic airway inflammation in several preclinical species. In a healthy volunteer Phase 1 study, treatment with GDC-0334 reduced TRPA1 agonist-induced DBF, pain, and itch, demonstrating GDC-0334 target engagement in humans. These data provide therapeutic rationale for evaluating TRPA1 inhibition as a clinical therapy for asthma.
Collapse
Affiliation(s)
- Alessia Balestrini
- Department of Immunology Discovery, Genentech, Inc., South San Francisco, CA
| | - Victory Joseph
- Department of Biomedical Imaging, Genentech, Inc., South San Francisco, CA
| | - Michelle Dourado
- Department of Neuroscience, Genentech, Inc., South San Francisco, CA
| | - Rebecca M Reese
- Department of Neuroscience, Genentech, Inc., South San Francisco, CA
| | - Shannon D Shields
- Department of Neuroscience, Genentech, Inc., South San Francisco, CA
| | - Lionel Rougé
- Department of Structural Biology, Genentech, Inc., South San Francisco, CA
| | - Daniel D Bravo
- Department of Biochemical and Cellular Pharmacology, Genentech, Inc., South San Francisco, CA
| | - Tania Chernov-Rogan
- Department of Biochemical and Cellular Pharmacology, Genentech, Inc., South San Francisco, CA
| | - Cary D Austin
- Department of Pathology, Genentech, Inc., South San Francisco, CA
| | - Huifen Chen
- Department of Discovery Chemistry, Genentech, Inc., South San Francisco, CA
| | - Lan Wang
- Department of Discovery Chemistry, Genentech, Inc., South San Francisco, CA
| | - Elisia Villemure
- Department of Discovery Chemistry, Genentech, Inc., South San Francisco, CA
| | - Daniel G M Shore
- Department of Discovery Chemistry, Genentech, Inc., South San Francisco, CA
| | - Vishal A Verma
- Department of Discovery Chemistry, Genentech, Inc., South San Francisco, CA
| | - Baihua Hu
- Pharmaron-Beijing Co. Ltd., BDA, Beijing, People's Republic of China
| | - Yong Chen
- Pharmaron-Beijing Co. Ltd., BDA, Beijing, People's Republic of China
| | - Laurie Leong
- Department of Pathology, Genentech, Inc., South San Francisco, CA
| | - Chris Bjornson
- Department of Pathology, Genentech, Inc., South San Francisco, CA
| | - Kathy Hötzel
- Department of Pathology, Genentech, Inc., South San Francisco, CA
| | - Alvin Gogineni
- Department of Biomedical Imaging, Genentech, Inc., South San Francisco, CA
| | - Wyne P Lee
- Department of Translational Immunology, Genentech, Inc., South San Francisco, CA
| | - Eric Suto
- Department of Translational Immunology, Genentech, Inc., South San Francisco, CA
| | - Xiumin Wu
- Department of Translational Immunology, Genentech, Inc., South San Francisco, CA
| | - John Liu
- Department of Translational Immunology, Genentech, Inc., South San Francisco, CA
| | - Juan Zhang
- Department of Translational Immunology, Genentech, Inc., South San Francisco, CA
| | - Vineela Gandham
- Department of Biomedical Imaging, Genentech, Inc., South San Francisco, CA
| | - Jianyong Wang
- Department of Biochemical and Cellular Pharmacology, Genentech, Inc., South San Francisco, CA
| | - Jian Payandeh
- Department of Structural Biology, Genentech, Inc., South San Francisco, CA
| | - Claudio Ciferri
- Department of Structural Biology, Genentech, Inc., South San Francisco, CA
| | - Alberto Estevez
- Department of Structural Biology, Genentech, Inc., South San Francisco, CA
| | | | - Jens Kortmann
- Department of Immunology Discovery, Genentech, Inc., South San Francisco, CA
| | - Ryan L Wong
- Department of Immunology Discovery, Genentech, Inc., South San Francisco, CA
| | - Jose E Heredia
- Department of Immunology Discovery, Genentech, Inc., South San Francisco, CA
| | - Jonas Doerr
- Department of Molecular Biology, Genentech, Inc., South San Francisco, CA
| | - Min Jung
- Department of OMNI Bioinformatics, Genentech, Inc., South San Francisco, CA
| | | | - Merone Roose-Girma
- Department of Molecular Biology, Genentech, Inc., South San Francisco, CA
| | - Lucinda Tam
- Department of Molecular Biology, Genentech, Inc., South San Francisco, CA
| | - Kai H Barck
- Department of Biomedical Imaging, Genentech, Inc., South San Francisco, CA
| | - Richard A D Carano
- Department of Biomedical Imaging, Genentech, Inc., South San Francisco, CA
| | - Han Ting Ding
- Department of Clinical Pharmacology, Genentech, Inc., South San Francisco, CA
| | - Bobby Brillantes
- Department of Biomolecular Resources, Genentech, Inc., South San Francisco, CA
| | - Christine Tam
- Department of Biomolecular Resources, Genentech, Inc., South San Francisco, CA
| | - Xiaoying Yang
- Department of Product Development Biometric Biostatistics, Genentech, Inc., South San Francisco, CA
| | - Simon S Gao
- Department of Clinical Imaging, Genentech, Inc., South San Francisco, CA
| | - Justin Q Ly
- Department of Drug Metabolism and Pharmacokinetics, Genentech, Inc., South San Francisco, CA
| | - Liling Liu
- Department of Drug Metabolism and Pharmacokinetics, Genentech, Inc., South San Francisco, CA
| | - Liuxi Chen
- Department of Drug Metabolism and Pharmacokinetics, Genentech, Inc., South San Francisco, CA
| | - Bianca M Liederer
- Department of Drug Metabolism and Pharmacokinetics, Genentech, Inc., South San Francisco, CA
| | - Joseph H Lin
- Department of Early Clinical Development, Genentech, Inc., South San Francisco, CA
| | - Steven Magnuson
- Department of Discovery Chemistry, Genentech, Inc., South San Francisco, CA
| | - Jun Chen
- Department of Biochemical and Cellular Pharmacology, Genentech, Inc., South San Francisco, CA
| | - David H Hackos
- Department of Neuroscience, Genentech, Inc., South San Francisco, CA
| | - Justin Elstrott
- Department of Biomedical Imaging, Genentech, Inc., South San Francisco, CA
| | - Alexis Rohou
- Department of Structural Biology, Genentech, Inc., South San Francisco, CA
| | - Brian S Safina
- Department of Discovery Chemistry, Genentech, Inc., South San Francisco, CA
| | - Matthew Volgraf
- Department of Discovery Chemistry, Genentech, Inc., South San Francisco, CA
| | - Rebecca N Bauer
- Department of OMNI-Biomarker Development, Genentech, Inc., South San Francisco, CA
| | - Lorena Riol-Blanco
- Department of Immunology Discovery, Genentech, Inc., South San Francisco, CA
| |
Collapse
|
7
|
Abstract
The ubiquitin proteasome system (UPS) presents many opportunities for pharmacological intervention. Key players in the UPS are E3 ubiquitin ligases, responsible for conjugation of ubiquitin to specific cognate substrates. Numbering more than 600 members, these ligases represent the most selective way to intervene within this physiologically important system. This Perspective highlights some of the dedicated medicinal chemistry efforts directed at inhibiting the function of specific single-protein and multicomponent RING-type E3 ubiquitin ligases. We present opportunities and challenges associated with targeting this important class of enzymes.
Collapse
Affiliation(s)
- Nicole Blaquiere
- Discovery Chemistry, Genentech Inc., 1 DNA Way, South San Francisco, California 94080, United States
| | - Elisia Villemure
- Discovery Chemistry, Genentech Inc., 1 DNA Way, South San Francisco, California 94080, United States
| | - Steven T Staben
- Discovery Chemistry, Genentech Inc., 1 DNA Way, South San Francisco, California 94080, United States
| |
Collapse
|
8
|
Chen H, Volgraf M, Do S, Kolesnikov A, Shore DG, Verma VA, Villemure E, Wang L, Chen Y, Hu B, Lu AJ, Wu G, Xu X, Yuen PW, Zhang Y, Erickson SD, Dahl M, Brotherton-Pleiss C, Tay S, Ly JQ, Murray LJ, Chen J, Amm D, Lange W, Hackos DH, Reese RM, Shields SD, Lyssikatos JP, Safina BS, Estrada AA. Discovery of a Potent (4R,5S)-4-Fluoro-5-methylproline Sulfonamide Transient Receptor Potential Ankyrin 1 Antagonist and Its Methylene Phosphate Prodrug Guided by Molecular Modeling. J Med Chem 2018; 61:3641-3659. [DOI: 10.1021/acs.jmedchem.8b00117] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/23/2023]
Affiliation(s)
| | | | | | | | | | | | | | | | - Yong Chen
- Pharmaron-Beijing Co. Ltd., 6 Taihe Road, BDA, Beijing 100176, P. R. China
| | - Baihua Hu
- Pharmaron-Beijing Co. Ltd., 6 Taihe Road, BDA, Beijing 100176, P. R. China
| | - Ai-Jun Lu
- Pharmaron-Beijing Co. Ltd., 6 Taihe Road, BDA, Beijing 100176, P. R. China
| | - Guosheng Wu
- Pharmaron-Beijing Co. Ltd., 6 Taihe Road, BDA, Beijing 100176, P. R. China
| | - Xiaofeng Xu
- Pharmaron-Beijing Co. Ltd., 6 Taihe Road, BDA, Beijing 100176, P. R. China
| | - Po-wai Yuen
- Pharmaron-Beijing Co. Ltd., 6 Taihe Road, BDA, Beijing 100176, P. R. China
| | - Yamin Zhang
- Pharmaron-Beijing Co. Ltd., 6 Taihe Road, BDA, Beijing 100176, P. R. China
| | - Shawn D. Erickson
- Small Molecule Research, Pharmaceutical Research and Early Drug Development, Hoffmann-La Roche Inc., 340 Kingsland Street, Nutley, New Jersey 07110, United States
| | - Martin Dahl
- Small Molecule Research, Pharmaceutical Research and Early Drug Development, Hoffmann-La Roche Inc., 340 Kingsland Street, Nutley, New Jersey 07110, United States
| | - Christine Brotherton-Pleiss
- Small Molecule Research, Pharmaceutical Research and Early Drug Development, Hoffmann-La Roche Inc., 340 Kingsland Street, Nutley, New Jersey 07110, United States
| | | | | | | | | | - Desiree Amm
- Ion Channels Group, Evotec AG, Manfred Eigen Campus, Essener Bogen 7, 22419 Hamburg, Germany
| | - Wienke Lange
- Ion Channels Group, Evotec AG, Manfred Eigen Campus, Essener Bogen 7, 22419 Hamburg, Germany
| | | | | | | | | | | | | |
Collapse
|
9
|
Villemure E, Volgraf M, Jiang Y, Wu G, Ly CQ, Yuen PW, Lu A, Luo X, Liu M, Zhang S, Lupardus PJ, Wallweber HJA, Liederer BM, Deshmukh G, Plise E, Tay S, Wang TM, Hanson JE, Hackos DH, Scearce-Levie K, Schwarz JB, Sellers BD. GluN2A-Selective Pyridopyrimidinone Series of NMDAR Positive Allosteric Modulators with an Improved in Vivo Profile. ACS Med Chem Lett 2017; 8:84-89. [PMID: 28105280 DOI: 10.1021/acsmedchemlett.6b00388] [Citation(s) in RCA: 22] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/04/2016] [Accepted: 10/31/2016] [Indexed: 11/28/2022] Open
Abstract
The N-methyl-d-aspartate receptor (NMDAR) is an ionotropic glutamate receptor, gated by the endogenous coagonists glutamate and glycine, permeable to Ca2+ and Na+. NMDAR dysfunction is associated with numerous neurological and psychiatric disorders, including schizophrenia, depression, and Alzheimer's disease. Recently, we have disclosed GNE-0723 (1), a GluN2A subunit-selective and brain-penetrant positive allosteric modulator (PAM) of NMDARs. This work highlights the discovery of a related pyridopyrimidinone core with distinct structure-activity relationships, despite the structural similarity to GNE-0723. GNE-5729 (13), a pyridopyrimidinone-based NMDAR PAM, was identified with both an improved pharmacokinetic profile and increased selectivity against AMPARs. We also include X-ray structure analysis and modeling to propose hypotheses for the activity and selectivity differences.
Collapse
Affiliation(s)
| | | | - Yu Jiang
- Pharmaron-Beijing Co. Ltd., 6 Taihe Road,
BDA, Beijing 100176, PR China
| | - Guosheng Wu
- Pharmaron-Beijing Co. Ltd., 6 Taihe Road,
BDA, Beijing 100176, PR China
| | | | - Po-wai Yuen
- Pharmaron-Beijing Co. Ltd., 6 Taihe Road,
BDA, Beijing 100176, PR China
| | - Aijun Lu
- Pharmaron-Beijing Co. Ltd., 6 Taihe Road,
BDA, Beijing 100176, PR China
| | - Xifeng Luo
- Pharmaron-Beijing Co. Ltd., 6 Taihe Road,
BDA, Beijing 100176, PR China
| | - Mingcui Liu
- Pharmaron-Beijing Co. Ltd., 6 Taihe Road,
BDA, Beijing 100176, PR China
| | - Shun Zhang
- Pharmaron-Beijing Co. Ltd., 6 Taihe Road,
BDA, Beijing 100176, PR China
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
10
|
Siu M, Huestis M, Liao H, Li A, Chen X, Liang K, Shen Y, Liang Q, Xu K, Shore D, Villemure E. Preparation of 2-Azabicyclo[2.1.1]hexane Hydrochloride. Synlett 2016. [DOI: 10.1055/s-0035-1562380] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
Affiliation(s)
| | | | | | | | | | | | | | | | - Kewei Xu
- Discovery Chemistry, Genentech, Inc
| | | | | |
Collapse
|
11
|
Volgraf M, Sellers BD, Jiang Y, Wu G, Ly CQ, Villemure E, Pastor RM, Yuen PW, Lu A, Luo X, Liu M, Zhang S, Sun L, Fu Y, Lupardus PJ, Wallweber HJA, Liederer BM, Deshmukh G, Plise E, Tay S, Reynen P, Herrington J, Gustafson A, Liu Y, Dirksen A, Dietz MGA, Liu Y, Wang TM, Hanson JE, Hackos D, Scearce-Levie K, Schwarz JB. Discovery of GluN2A-Selective NMDA Receptor Positive Allosteric Modulators (PAMs): Tuning Deactivation Kinetics via Structure-Based Design. J Med Chem 2016; 59:2760-79. [PMID: 26919761 DOI: 10.1021/acs.jmedchem.5b02010] [Citation(s) in RCA: 71] [Impact Index Per Article: 8.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2022]
Abstract
The N-methyl-D-aspartate receptor (NMDAR) is a Na(+) and Ca(2+) permeable ionotropic glutamate receptor that is activated by the coagonists glycine and glutamate. NMDARs are critical to synaptic signaling and plasticity, and their dysfunction has been implicated in a number of neurological disorders, including schizophrenia, depression, and Alzheimer's disease. Herein we describe the discovery of potent GluN2A-selective NMDAR positive allosteric modulators (PAMs) starting from a high-throughput screening hit. Using structure-based design, we sought to increase potency at the GluN2A subtype, while improving selectivity against related α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptors (AMPARs). The structure-activity relationship of channel deactivation kinetics was studied using a combination of electrophysiology and protein crystallography. Effective incorporation of these strategies resulted in the discovery of GNE-0723 (46), a highly potent and brain penetrant GluN2A-selective NMDAR PAM suitable for in vivo characterization.
Collapse
Affiliation(s)
| | | | - Yu Jiang
- Pharmaron-Beijing Co. Ltd. , 6 Taihe Road, BDA, Beijing 100176, PR China
| | - Guosheng Wu
- Pharmaron-Beijing Co. Ltd. , 6 Taihe Road, BDA, Beijing 100176, PR China
| | | | | | | | - Po-wai Yuen
- Pharmaron-Beijing Co. Ltd. , 6 Taihe Road, BDA, Beijing 100176, PR China
| | - Aijun Lu
- Pharmaron-Beijing Co. Ltd. , 6 Taihe Road, BDA, Beijing 100176, PR China
| | - Xifeng Luo
- Pharmaron-Beijing Co. Ltd. , 6 Taihe Road, BDA, Beijing 100176, PR China
| | - Mingcui Liu
- Pharmaron-Beijing Co. Ltd. , 6 Taihe Road, BDA, Beijing 100176, PR China
| | - Shun Zhang
- Pharmaron-Beijing Co. Ltd. , 6 Taihe Road, BDA, Beijing 100176, PR China
| | - Liang Sun
- Pharmaron-Beijing Co. Ltd. , 6 Taihe Road, BDA, Beijing 100176, PR China
| | - Yuhong Fu
- Pharmaron-Beijing Co. Ltd. , 6 Taihe Road, BDA, Beijing 100176, PR China
| | | | | | | | | | | | | | | | | | | | | | - Akim Dirksen
- Ion Channels Group, Evotec AG ; Manfred Eigen Campus, Essener Bogen 7, 22419 Hamburg, Germany
| | - Matthias G A Dietz
- Ion Channels Group, Evotec AG ; Manfred Eigen Campus, Essener Bogen 7, 22419 Hamburg, Germany
| | | | | | | | | | | | | |
Collapse
|
12
|
Moreau B, O’Meara JA, Bordeleau J, Garneau M, Godbout C, Gorys V, Leblanc M, Villemure E, White PW, Llinàs-Brunet M. Discovery of Hepatitis C Virus NS3-4A Protease Inhibitors with Improved Barrier to Resistance and Favorable Liver Distribution. J Med Chem 2013; 57:1770-6. [DOI: 10.1021/jm400121t] [Citation(s) in RCA: 26] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/08/2023]
Affiliation(s)
- Benoît Moreau
- Department of Medicinal Chemistry and ‡Department of Biological
Sciences, Research and Development, Boehringer Ingelheim (Canada) Ltd., 2100 Cunard Street, Laval,
Quebec H7S 2G5, Canada
| | - Jeff A. O’Meara
- Department of Medicinal Chemistry and ‡Department of Biological
Sciences, Research and Development, Boehringer Ingelheim (Canada) Ltd., 2100 Cunard Street, Laval,
Quebec H7S 2G5, Canada
| | - Josée Bordeleau
- Department of Medicinal Chemistry and ‡Department of Biological
Sciences, Research and Development, Boehringer Ingelheim (Canada) Ltd., 2100 Cunard Street, Laval,
Quebec H7S 2G5, Canada
| | - Michel Garneau
- Department of Medicinal Chemistry and ‡Department of Biological
Sciences, Research and Development, Boehringer Ingelheim (Canada) Ltd., 2100 Cunard Street, Laval,
Quebec H7S 2G5, Canada
| | - Cedrickx Godbout
- Department of Medicinal Chemistry and ‡Department of Biological
Sciences, Research and Development, Boehringer Ingelheim (Canada) Ltd., 2100 Cunard Street, Laval,
Quebec H7S 2G5, Canada
| | - Vida Gorys
- Department of Medicinal Chemistry and ‡Department of Biological
Sciences, Research and Development, Boehringer Ingelheim (Canada) Ltd., 2100 Cunard Street, Laval,
Quebec H7S 2G5, Canada
| | - Mélissa Leblanc
- Department of Medicinal Chemistry and ‡Department of Biological
Sciences, Research and Development, Boehringer Ingelheim (Canada) Ltd., 2100 Cunard Street, Laval,
Quebec H7S 2G5, Canada
| | - Elisia Villemure
- Department of Medicinal Chemistry and ‡Department of Biological
Sciences, Research and Development, Boehringer Ingelheim (Canada) Ltd., 2100 Cunard Street, Laval,
Quebec H7S 2G5, Canada
| | - Peter W. White
- Department of Medicinal Chemistry and ‡Department of Biological
Sciences, Research and Development, Boehringer Ingelheim (Canada) Ltd., 2100 Cunard Street, Laval,
Quebec H7S 2G5, Canada
| | - Montse Llinàs-Brunet
- Department of Medicinal Chemistry and ‡Department of Biological
Sciences, Research and Development, Boehringer Ingelheim (Canada) Ltd., 2100 Cunard Street, Laval,
Quebec H7S 2G5, Canada
| |
Collapse
|
13
|
Campeau LC, Stuart DR, Leclerc JP, Bertrand-Laperle M, Villemure E, Sun HY, Lasserre S, Guimond N, Lecavallier M, Fagnou K. Palladium-Catalyzed Direct Arylation of Azine and Azole N-Oxides: Reaction Development, Scope and Applications in Synthesis. J Am Chem Soc 2009; 131:3291-306. [DOI: 10.1021/ja808332k] [Citation(s) in RCA: 368] [Impact Index Per Article: 24.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
Affiliation(s)
- Louis-Charles Campeau
- Center for Catalysis Research and Innovation, Department of Chemistry, University of Ottawa, 10 Marie Curie, Ottawa, Canada K1N 6N5
| | - David R. Stuart
- Center for Catalysis Research and Innovation, Department of Chemistry, University of Ottawa, 10 Marie Curie, Ottawa, Canada K1N 6N5
| | - Jean-Philippe Leclerc
- Center for Catalysis Research and Innovation, Department of Chemistry, University of Ottawa, 10 Marie Curie, Ottawa, Canada K1N 6N5
| | - Mégan Bertrand-Laperle
- Center for Catalysis Research and Innovation, Department of Chemistry, University of Ottawa, 10 Marie Curie, Ottawa, Canada K1N 6N5
| | - Elisia Villemure
- Center for Catalysis Research and Innovation, Department of Chemistry, University of Ottawa, 10 Marie Curie, Ottawa, Canada K1N 6N5
| | - Ho-Yan Sun
- Center for Catalysis Research and Innovation, Department of Chemistry, University of Ottawa, 10 Marie Curie, Ottawa, Canada K1N 6N5
| | - Sandrine Lasserre
- Center for Catalysis Research and Innovation, Department of Chemistry, University of Ottawa, 10 Marie Curie, Ottawa, Canada K1N 6N5
| | - Nicolas Guimond
- Center for Catalysis Research and Innovation, Department of Chemistry, University of Ottawa, 10 Marie Curie, Ottawa, Canada K1N 6N5
| | - Melanie Lecavallier
- Center for Catalysis Research and Innovation, Department of Chemistry, University of Ottawa, 10 Marie Curie, Ottawa, Canada K1N 6N5
| | - Keith Fagnou
- Center for Catalysis Research and Innovation, Department of Chemistry, University of Ottawa, 10 Marie Curie, Ottawa, Canada K1N 6N5
| |
Collapse
|
14
|
Rew Y, McMinn DL, Wang Z, He X, Hungate RW, Jaen JC, Sudom A, Sun D, Tu H, Ursu S, Villemure E, Walker NPC, Yan X, Ye Q, Powers JP. Discovery and optimization of piperidyl benzamide derivatives as a novel class of 11beta-HSD1 inhibitors. Bioorg Med Chem Lett 2009; 19:1797-801. [PMID: 19217779 DOI: 10.1016/j.bmcl.2009.01.058] [Citation(s) in RCA: 24] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/16/2008] [Revised: 01/15/2009] [Accepted: 01/16/2009] [Indexed: 11/16/2022]
Abstract
Discovery and optimization of a piperidyl benzamide series of 11beta-HSD1 inhibitors is described. This series was derived from a cyclohexyl benzamide lead structures to address PXR selectivity, high non-specific protein binding, poor solubility, limited in vivo exposure, and in vitro cytotoxicity issues observed with the cyclohexyl benzamide structures. These efforts led to the discovery of piperidyl benzamide 15 which features improved properties over the cyclohexyl benzamide derivatives.
Collapse
Affiliation(s)
- Yosup Rew
- Amgen Inc., 1120 Veterans Boulevard, South San Francisco, CA 94080, USA
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
15
|
Campeau LC, Bertrand-Laperle M, Leclerc JP, Villemure E, Gorelsky S, Fagnou K. C2, C5, and C4 azole N-oxide direct arylation including room-temperature reactions. J Am Chem Soc 2008; 130:3276-7. [PMID: 18302383 DOI: 10.1021/ja7107068] [Citation(s) in RCA: 246] [Impact Index Per Article: 15.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Affiliation(s)
- Louis-Charles Campeau
- Center for Catalysis Research and Innovation, Department of Chemistry, University of Ottawa, 10 Marie Curie, Ottawa, Ontario, Canada K1N 6N5
| | | | | | | | | | | |
Collapse
|
16
|
Affiliation(s)
- David R Stuart
- Center for Catalysis Research and Innovation, University of Ottawa, Department of Chemistry, 10 Marie Curie, Ottawa, Ontario, Canada
| | | | | |
Collapse
|